Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Epetraborole in Healthy Adults
NCT04892641Phase 1Completed
- Sponsor
- AN2 Therapeutics, Inc.
- Start
- Jun 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of epetraborole in nontuberculous mycobacterial lung disease and Mycobacterium avium complex lung disease, sponsored by AN2 Therapeutics, Inc. Primary endpoints: Treatment Emergent Adverse Events, Physical Examination Abnormalities and 11 more. Started Jun 2021; status: completed.
02
Drugs
epetraborole
03
Conditions
nontuberculous mycobacterial lung diseaseMycobacterium avium complex lung disease
Beyond the preview
Go deeper on NCT04892641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04892641.